Federal Circuit Rules in Favor of Natera, Upholding Invalidation of CareDx Patents
Natera, Inc. (NASDAQ: NTRA) announced that the Federal Circuit Court of Appeals has upheld the invalidation of three CareDx patents, affirming a prior 2021 ruling. This decision is seen as a significant legal victory for Natera, reinforcing its position in the genetic testing market, particularly in cfDNA testing for transplant patients. Chief legal officer Daniel Rabinowitz expressed satisfaction with the court's rejection of CareDx's claims, emphasizing Natera's commitment to innovation and service in the transplant community.
- Federal Circuit Court ruled in favor of Natera, validating the invalidation of CareDx patents.
- Legal victory strengthens Natera's position in cfDNA testing market.
- Natera continues to focus on innovation in transplant-related genetic testing.
- None.
AUSTIN, Texas, July 18, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that the Federal Circuit Court of Appeals affirmed the Delaware Federal District Court's September 2021 decision that all three CareDx patents asserted against Natera are invalid for claiming patent-ineligible subject matter.
"We are pleased that multiple courts have rejected CareDx's baseless claims against Natera's proprietary technology," said Daniel Rabinowitz, chief legal officer, Natera. "Natera is a leading innovator of cfDNA testing, and we remain focused on serving the transplant community, including our many physician partners and patients."
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights, and our expectations of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Kate Stabrawa, Communications, Natera, Inc., pr@natera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/federal-circuit-rules-in-favor-of-natera-upholding-invalidation-of-caredx-patents-301588373.html
SOURCE Natera, Inc.
